Novel homozygous BMP9 nonsense mutation causes pulmonary arterial hypertension: a case report
Open Access
- 22 January 2016
- journal article
- case report
- Published by Springer Science and Business Media LLC in BMC Pulmonary Medicine
- Vol. 16 (1), 1-4
- https://doi.org/10.1186/s12890-016-0183-7
Abstract
Pulmonary arterial hypertension (PAH) is a rare, progressive, fatal vascular disorder. Genetic predisposition plays vital roles in the development of PAH, with most mutations being identified in genes involved in the transforming growth factor beta (TGF-β) signaling pathways. Defects in the BMP9 gene have been documented in hereditary hemorrhagic telangiectasia (HHT), the most common inherited vascular disorder, which is occasionally associated with PAH. Selective enhancement of endothelial BMPR2 with BMP9 reverses pulmonary arterial hypertension. We report the case of a 5-year-old Hispanic boy who was diagnosed with severe PAH and right heart failure at 3 years of age. During his stay in the pediatric intensive care unit, treatment was initiated with inhaled nitric oxide and intravenous epoprostenol; he subsequently was transitioned to treprostinil, sildenafil, and prophylactic enoxaparin. Now, two years later, the child is asymptomatic on sildenafil, bosentan, subcutaneous treprostinil, and warfarin. Genetic screening revealed a novel homozygous nonsense mutation in the BMP9 gene (c.76C > T; p.Gln26Ter). The child had no telangiectasias or arteriovenous malformations; family history also was negative. Subsequent parental testing showed both parents were heterozygous for the same mutation, indicating that the child inherited the BMP9 mutant allele from each parent. To our knowledge, this is the first report of a BMP9 mutation in a patient with PAH. The homozygous nonsense mutation may account for the early onset and severity of PAH in this patient and also fit the ‘two-hit’ model we proposed previously. The absence of clinical symptoms for PAH in the parents may be due to incomplete penetrance or various expressivities of the BMP9 mutations. Our study expands the spectrum of phenotypes related to BMP9 mutations.Keywords
This publication has 12 references indexed in Scilit:
- Pulmonary Arterial Hypertension: A Current Perspective on Established and Emerging Molecular Genetic DefectsHuman Mutation, 2015
- Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertensionNature Medicine, 2015
- Early onset severe pulmonary arterial hypertension with ‘two-hit’ digenic mutations in both BMPR2 and KCNA5 genesInternational Journal of Cardiology, 2014
- Functional analysis of endoglin mutations from hereditary hemorrhagic telangiectasia type 1 patients reveals different mechanisms for endoglin loss of functionHuman Molecular Genetics, 2014
- Mutations of NOTCH3 in childhood pulmonary arterial hypertensionMolecular Genetics & Genomic Medicine, 2014
- Definitions and Diagnosis of Pulmonary HypertensionJournal of the American College of Cardiology, 2013
- Genetics and Genomics of Pulmonary Arterial HypertensionJournal of the American College of Cardiology, 2013
- BMP9 Mutations Cause a Vascular-Anomaly Syndrome with Phenotypic Overlap with Hereditary Hemorrhagic TelangiectasiaAmerican Journal of Human Genetics, 2013
- Bone Morphogenetic Protein (BMP) and Activin Type II Receptors Balance BMP9 Signals Mediated by Activin Receptor-like Kinase-1 in Human Pulmonary Artery Endothelial CellsPublished by Elsevier BV ,2009
- Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cellsBlood, 2006